openPR Logo
Press release

Metabolic Disorders Therapeutics Market 2020: A Latest Research Report to Share Market Insights with Top Key Vendors (AbbVie, Novo Nordisk, Sanofi, Merck, Boehringer Ingelheim, Eli Lilly) | Forecast to 2025

07-31-2020 06:43 PM CET | Health & Medicine

Press release from: Business Industry Reports

Metabolic Disorders Therapeutics Market

Metabolic Disorders Therapeutics Market

Overview of Global Metabolic Disorders Therapeutics Market:

This report provides in-depth study of “Global Metabolic Disorders Therapeutics Market 2020” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Metabolic Disorders Therapeutics Market report also provides an in-depth survey of key players in the market organization.

Major key factors driving the growth of the Global Metabolic Disorders Therapeutics Market are increase in the cases of metabolic disorders, rise in awareness about the availability of therapeutics for metabolic disorders, increase in demand for one-time therapies for metabolic disorders, commencement of patient assistance programs for providing treatment for a range of metabolic disorders, rapid advancements in technology, rise in the prevalence of diabetes and obesity, and initiatives were undertaken by the government.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273410 .

Firstly, the report provides a basic overview of the Market including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major Market players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2020-2025 market shares for each company.

Based on the regional analysis, North America is the dominant region of this market due to the presence of major companies. Increasing prevalence of obesity and diabetes in the region is another factor responsible for its largest share. APAC is said to witness the greatest CAGR value during the estimated time owing to the rapid economic development in this region. Changing lifestyles, leading to a rise in obesity, diabetes, and hypercholesterolemia diseases, along with increased disposable income levels are driving the APAC market.

In the end, the report makes some important proposals for a new project of Metabolic Disorders Therapeutics Market before evaluating its feasibility. Overall, the report provides an in-depth insight of 2013-2025 global Metabolic Disorders Therapeutics market covering all important parameters.

Global Key Vendors:

1 AbbVie

2 Novo Nordisk

3 Actelion Pharmaceuticals

4 Sanofi

5 Biocon

6 Merck

7 Boehringer Ingelheim

8 AstraZeneca

9 CymaBay Therapeutics

10 Eli Lilly and Company and More……………….

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Metabolic Disorders Therapeutics Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273410/single .

Product Type Segmentation

1 Metachromatic Leukodystrophy

2 Globoid Leukodystrophy

3 Hepatic Encephalopathy

Industry Segmentation

1 Diabetes

2 Obesity

3 Hypercholesterolemia

4 Lysosomal Storage Diseases

Global Medical Industry News:

Boehringer Ingelheim (July 07, 2020) - Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases - Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life changing breakthrough therapies with Numab’s multi-specific antibody platform.

Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheim’s research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheim’s growing cancer immunology portfolio and supports the strategy to take cancer on by targeting ‘cold’ tumors with synergistic combination approaches. In retinal diseases Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the company’s comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.

“We are thrilled to work with the excellent team at Numab to advance our portfolio assets.  Numab’s technology platform fits well with our internal antibody discovery and engineering capabilities and will enhance our efforts to deliver transformative antibody-based therapeutics to patients,” said Paige Mahaney, SVP and US Discovery Research Site Head at Boehringer Ingelheim.

“We are looking forward to working with Boehringer Ingelheim, a global leader in pharmaceutical R&D with profound expertise across a broad spectrum of therapeutic areas, further validating our technology platform. This addition to our growing roster of partnerships represents another key milestone in our business development efforts,” commented Dr. Oliver Middendorp, Chief Business Officer of Numab Therapeutics. “The upfront payment and near-term milestones attached to this alliance will further strengthen Numab’s ability to accelerate the development of key proprietary assets.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273410 .

Major Points in Table of Contents:

Global Metabolic Disorders Therapeutics Market Report 2020

1 Metabolic Disorders Therapeutics Product Definition

2 Global Metabolic Disorders Therapeutics Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Metabolic Disorders Therapeutics Shipments

2.2 Global Manufacturer Metabolic Disorders Therapeutics Business Revenue

2.3 Global Metabolic Disorders Therapeutics Market Overview

2.4 COVID-19 Impact on Metabolic Disorders Therapeutics Industry

3 Manufacturer Metabolic Disorders Therapeutics Business Introduction

3.1 AbbVie Metabolic Disorders Therapeutics Business Introduction

3.2 Novo Nordisk Metabolic Disorders Therapeutics Business Introduction

3.3 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Business Introduction

3.4 Sanofi Metabolic Disorders Therapeutics Business Introduction

3.5 Biocon Metabolic Disorders Therapeutics Business Introduction

3.6 Merck Metabolic Disorders Therapeutics Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metabolic Disorders Therapeutics Market 2020: A Latest Research Report to Share Market Insights with Top Key Vendors (AbbVie, Novo Nordisk, Sanofi, Merck, Boehringer Ingelheim, Eli Lilly) | Forecast to 2025 here

News-ID: 2101220 • Views: 343

More Releases from Business Industry Reports

2020-2025 Neoantigen Targeted Therapies Market to witness astonishing growth wit …
Global Neoantigen Targeted Therapies Market Synopsis: The report covers a forecast and an analysis of the Neoantigen Targeted Therapies Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Neoantigen Targeted Therapies Market along with the impact they have
Outstanding Scope of Nasojejunal Tube Market is Estimated to Grow Incredible CAG …
Overview of Global Nasojejunal Tube Market: This report provides in-depth study of “Global Nasojejunal Tube Market 2020” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Nasojejunal Tube Market report also provides an in-depth survey of key players in the market organization. The 'Global Nasojejunal Tube Industry, Market Research Report' is a professional and in-depth study on the current state of the global Nasojejunal Tube Market with a
Huge Investment in mTOR Inhibitors Market Expected to Witness the Highest Growth …
Global mTOR Inhibitors Market Synopsis: The exclusive research report on the Global mTOR Inhibitors Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global mTOR Inhibitors Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. According to the market research study, Mammalian Target Of Rapamycin (mTOR) is
SWOT Analysis of mRNA Treatment Market Excessive Growth Opportunities Estimated …
The exclusive research report on the Global mRNA Treatment Market 2020 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global mRNA Treatment Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. Overview of Global mRNA Treatment Market: This report studies the Global mRNA Treatment Market over the forecast

All 5 Releases


More Releases for Therapeutics

Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy. Download the sample report @ https://www.pharmaproff.com/request-sample/1077 Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy. Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis The
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other